Literature DB >> 24823457

Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20).

Yoriko Heianza1, Yasuji Arase, Hiroshi Tsuji, Kazuya Fujihara, Kazumi Saito, Shiun Dong Hsieh, Shiro Tanaka, Satoru Kodama, Shigeko Hara, Hirohito Sone.   

Abstract

OBJECTIVE: We investigated whether the metabolically healthy obese (MHO) phenotype was associated with an increased risk of the development of diabetes. If so, we aimed to determine what factors could explain this finding. DESIGN, SETTING, AND PARTICIPANTS: Studied were 8090 Japanese individuals without diabetes. Metabolic health status was assessed by common clinical markers: blood pressure, triglycerides, high-density lipoprotein-cholesterol, and fasting glucose concentrations. The cutoff value for obesity or normal weight (NW) was a body mass index of 25.0 kg/m(2).
RESULTS: The 5-year incidence rate of diabetes was 1.2% (n = 58 of 4749) in metabolically healthy NW (MHNW) individuals, 2.8% (n = 20 of 719) in MHO individuals, 6.0% (n = 102 of 1709) in metabolically abnormal NW individuals, and 10.3% (n = 94 of 913) in metabolically abnormal obese individuals. Although MHO individuals had no or one metabolic factor, 47.8% had ultrasonographic fatty liver (FL). The MHO group had a significantly increased risk of diabetes compared with the MHNW group [multivariate adjusted odds ratio (OR) 2.23 (95% confidence interval [CI] 1.33, 3.75)], but this risk was attenuated after adjustment for FL. Compared with the MHNW/non-FL group, the risk of diabetes in the MHO/non-FL group was not significantly elevated [OR 1.01 (95% CI 0.35, 2.88)]. However, the MHO/FL and MHNW/FL groups had similarly elevated risks of diabetes [OR 4.09 (95% CI 2.20, 7.60) and 3.16 (1.78, 5.62), respectively].
CONCLUSIONS: Almost half of the MHO participants had FL, which partially explained the increased risk of diabetes among the obese phenotypes. The presence of FL should be evaluated to assess whether an individual was actually in a metabolically benign state for the prediction of diabetes.

Entities:  

Mesh:

Year:  2014        PMID: 24823457     DOI: 10.1210/jc.2013-4427

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  28 in total

1.  Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals.

Authors:  Yoshitaka Hashimoto; Masahide Hamaguchi; Takuya Fukuda; Akihiro Ohbora; Takao Kojima; Michiaki Fukui
Journal:  Endocrine       Date:  2017-05-16       Impact factor: 3.633

2.  Metabolically healthy obesity and risk of incident CKD.

Authors:  Yoshitaka Hashimoto; Muhei Tanaka; Hiroshi Okada; Takafumi Senmaru; Masahide Hamaguchi; Mai Asano; Masahiro Yamazaki; Yohei Oda; Goji Hasegawa; Hitoshi Toda; Naoto Nakamura; Michiaki Fukui
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-29       Impact factor: 8.237

Review 3.  β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.

Authors:  Yoshifumi Saisho
Journal:  World J Diabetes       Date:  2015-02-15

4.  Prevalence and characteristics of individuals without diabetes and hypertension who underwent bariatric surgery: lessons learned about metabolically healthy obese.

Authors:  Clare J Lee; Jeanne M Clark; Vivian Asamoah; Michael Schweitzer; Thomas Magnuson; Mariana Lazo
Journal:  Surg Obes Relat Dis       Date:  2014-06-19       Impact factor: 4.734

Review 5.  Obesity or obesities? Controversies on the association between body mass index and premature mortality.

Authors:  Ottavio Bosello; Maria Pia Donataccio; Massimo Cuzzolaro
Journal:  Eat Weight Disord       Date:  2016-06       Impact factor: 4.652

6.  Weight gain since age of 20 as risk of metabolic syndrome even in non-overweight individuals.

Authors:  Yoshitaka Hashimoto; Masahide Hamaguchi; Takuya Fukuda; Akihiro Obora; Takao Kojima; Michiaki Fukui
Journal:  Endocrine       Date:  2017-09-30       Impact factor: 3.633

7.  Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.

Authors:  Donghee Kim; Won Kim; Sae Kyung Joo; Jimin Han; Jung Ho Kim; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  J Gastroenterol       Date:  2019-09-18       Impact factor: 7.527

8.  Visceral and subcutaneous adipose tissue FDG uptake by PET/CT in metabolically healthy obese subjects.

Authors:  Adriana L Oliveira; Debora C Azevedo; Miriam A Bredella; Takara L Stanley; Martin Torriani
Journal:  Obesity (Silver Spring)       Date:  2014-12-17       Impact factor: 5.002

Review 9.  Definitions of Metabolic Health and Risk of Future Type 2 Diabetes in BMI Categories: A Systematic Review and Network Meta-analysis.

Authors:  Luca A Lotta; Ali Abbasi; Stephen J Sharp; Anna-Stina Sahlqvist; Dawn Waterworth; Julia M Brosnan; Robert A Scott; Claudia Langenberg; Nicholas J Wareham
Journal:  Diabetes Care       Date:  2015-11       Impact factor: 19.112

10.  Healthy obesity and objective physical activity.

Authors:  Joshua A Bell; Mark Hamer; Vincent T van Hees; Archana Singh-Manoux; Mika Kivimäki; Séverine Sabia
Journal:  Am J Clin Nutr       Date:  2015-07-08       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.